Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [21] Current immunotherapy in multiple sclerosis
    Bashir, K
    Whitaker, JN
    IMMUNOLOGY AND CELL BIOLOGY, 1998, 76 (01) : 55 - 64
  • [22] Treatment of multiple sclerosis: current concepts and future perspectives
    Buck, Dorothea
    Hemmer, Bernhard
    JOURNAL OF NEUROLOGY, 2011, 258 (10) : 1747 - 1762
  • [23] Current disease-modifying therapies in multiple sclerosis
    Kieseier, BC
    Hartung, HP
    SEMINARS IN NEUROLOGY, 2003, 23 (02) : 133 - 145
  • [24] Current recommendations for multiple sclerosis treatment in pregnancy and puerperium
    Ghezzi, Angelo
    Annovazzi, Pietro
    Portaccio, Emilio
    Cesari, Elana
    Amato, Maria P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (07) : 683 - 692
  • [25] Current and emerging therapies in multiple sclerosis: a systematic review
    Castro-Borrero, Wanda
    Graves, Donna
    Frohman, Teresa C.
    Flores, Angela Bates
    Hardeman, Paula
    Logan, Diana
    Orchard, Megan
    Greenberg, Benjamin
    Frohman, Elliot M.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2012, 5 (04) : 205 - 220
  • [26] Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs
    Tsareva, Ekaterina
    Kulakova, Olga
    Boyko, Alexey
    Favorova, Olga
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (03) : 103 - 115
  • [27] Current trials in multiple sclerosis: established evidence and future hopes
    Killestein, J
    Polman, CH
    CURRENT OPINION IN NEUROLOGY, 2005, 18 (03) : 253 - 260
  • [28] Current aspects of treatment for relapsing-remittent multiple sclerosis
    Thoemke, F.
    Zipp, F.
    NERVENHEILKUNDE, 2011, 30 (04) : 247 - 253
  • [29] Multiple Sclerosis and Pregnancy: Current Considerations
    Buraga, Ioan
    Popovici, Roxana-Elena
    SCIENTIFIC WORLD JOURNAL, 2014,
  • [30] Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
    Loleit, Verena
    Biberacher, Viola
    Hemmer, Bernhard
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (03) : 276 - 296
12345